Profusa (NVACW) FCF Margin (2024)
Profusa posted quarterly FCF Margin of 1536.36% for Q3 2024.
Profusa (NVACW) has 1 years of FCF Margin data on file, last reported at 1536.36% in Q3 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 8.20% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 6.89% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 25.51% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 3.29% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -1.28% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 6.68% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 37.67% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 3.98% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 15.44% |
| 10 | Profusa | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | -1,536.36% |